PDF(Pubmed)
Abstract：
India has a high prevalence of type 2 diabetes mellitus (T2DM) with unique clinical characteristics compared to other populations. Despite advancements in diabetes therapy, a significant number of patients in India still experience poor glycemic control and complications. Dipeptidyl peptidase-4 (DPP-4) inhibitors continue to be an important component of T2DM treatment due to their favorable efficacy and tolerability profile. Given the current scenario, there is a need to revisit the role of DPP-4 inhibitors in T2DM management in Indian patients. This consensus paper aims to provide guidance on the utilization of DPP-4 inhibitors in T2DM management from an Indian perspective. A consensus group of 100 experts developed recommendations based on an extensive literature review and discussions. The expert group emphasized the importance of timely glycemic control, combination therapy, and targeting the underlying pathophysiology of T2DM. The combinations of DPP-4 inhibitors with metformin and/or sodium-glucose transport protein-2 inhibitors are rationalized in this paper, considering their complementary mechanisms of action. This paper provides valuable insights for clinicians in optimizing the management of T2DM in the Indian population with the use of DPP-4 inhibitors and proposes an algorithm for selecting DPP-4 inhibitor-based therapies.
摘要：
与其他人群相比，印度2型糖尿病（T2DM）的患病率很高，具有独特的临床特征。尽管糖尿病治疗取得了进展，印度仍有相当数量的患者血糖控制不良和并发症.二肽基肽酶-4（DPP-4）抑制剂由于其良好的疗效和耐受性而仍然是T2DM治疗的重要组成部分。鉴于目前的情况，有必要重新审视DPP-4抑制剂在印度患者T2DM治疗中的作用.这份共识文件旨在从印度的角度为DPP-4抑制剂在T2DM管理中的应用提供指导。由100名专家组成的共识小组在广泛的文献回顾和讨论的基础上提出了建议。专家组强调了及时控制血糖的重要性，联合治疗,并针对T2DM的潜在病理生理学。本文对DPP-4抑制剂与二甲双胍和/或钠-葡萄糖转运蛋白-2抑制剂的组合进行了合理化，考虑到它们的互补作用机制。本文为临床医生在使用DPP-4抑制剂的印度人群中优化T2DM的管理提供了有价值的见解，并提出了选择基于DPP-4抑制剂的疗法的算法。
